GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » ROC (Joel Greenblatt) %

Onconetix (Onconetix) ROC (Joel Greenblatt) % : -23,097.60% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Onconetix ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Onconetix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -23,097.60%.

The historical rank and industry rank for Onconetix's ROC (Joel Greenblatt) % or its related term are showing as below:

ONCO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -103230.77   Med: -12571.43   Max: -1655.1
Current: -53763.22

During the past 5 years, Onconetix's highest ROC (Joel Greenblatt) % was -1655.10%. The lowest was -103230.77%. And the median was -12571.43%.

ONCO's ROC (Joel Greenblatt) % is ranked worse than
97.81% of 1459 companies
in the Biotechnology industry
Industry Median: -330.28 vs ONCO: -53763.22

Onconetix's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Onconetix ROC (Joel Greenblatt) % Historical Data

The historical data trend for Onconetix's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix ROC (Joel Greenblatt) % Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-12,571.43 -1,655.10 -3,400.00 -103,230.77 -32,960.54

Onconetix Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81,342.86 -190,028.57 -150,459.26 -79,909.91 -23,097.60

Competitive Comparison of Onconetix's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Onconetix's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onconetix's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Onconetix's ROC (Joel Greenblatt) % falls into.



Onconetix ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.15 + 0.364 + 0.77) - (7.007 + 0 + 0.49)
=-6.213

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.253 + 0.396 + 1.182) - (5.619 + 0 + 0.571)
=-4.359

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Onconetix for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.308/( ( (0.209 + max(-6.213, 0)) + (0.166 + max(-4.359, 0)) )/ 2 )
=-43.308/( ( 0.209 + 0.166 )/ 2 )
=-43.308/0.1875
=-23,097.60 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Onconetix  (NAS:ONCO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Onconetix ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Onconetix's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Onconetix (Onconetix) Business Description

Traded in Other Exchanges
Address
201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has a product named Entadfi an FDA approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Executives
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic director BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc 10 percent owner 2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc other: Manager-Cinti Cornerstone Inv. 2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez 10 percent owner, officer: CEO C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson officer: Chief Business Officer 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield officer: CFO 11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable director 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202

Onconetix (Onconetix) Headlines

From GuruFocus